Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research
Iberdomide has the potential to be the first approved CELMoD agent
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
Subscribe To Our Newsletter & Stay Updated
